← Back to Screener
Sight Sciences, Inc. Common Stock (SGHT)
Price$4.36
Favorite Metrics
Price vs S&P 500 (26W)19.07%
Price vs S&P 500 (4W)8.37%
Market Capitalization$220.88M
All Metrics
Book Value / Share (Quarterly)$1.20
P/TBV (Annual)0.94x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)2.74%
Cash Flow / Share (Quarterly)$-0.56
Price vs S&P 500 (YTD)-52.56%
Gross Margin (TTM)86.95%
Net Profit Margin (TTM)-49.67%
EPS (TTM)$-0.74
10-Day Avg Trading Volume0.18M
EPS Excl Extra (TTM)$-0.74
Revenue Growth (5Y)22.86%
EPS (Annual)$-0.74
ROI (Annual)-36.86%
Gross Margin (Annual)86.95%
Net Profit Margin (5Y Avg)-86.44%
Cash / Share (Quarterly)$1.72
Revenue Growth QoQ (YoY)6.87%
ROA (Last FY)-33.33%
Revenue Growth TTM (YoY)-3.13%
EBITD / Share (TTM)$-0.70
ROE (5Y Avg)-49.23%
Operating Margin (TTM)-47.96%
Cash Flow / Share (Annual)$-0.56
P/B Ratio3.45x
P/B Ratio (Quarterly)6.56x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.19x
Net Interest Coverage (TTM)-31.86x
ROA (TTM)-31.81%
EPS Incl Extra (Annual)$-0.74
Current Ratio (Annual)10.22x
Quick Ratio (Quarterly)9.22x
3-Month Avg Trading Volume0.31M
52-Week Price Return56.70%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.61
P/S Ratio (Annual)2.86x
Asset Turnover (Annual)0.67x
52-Week High$9.24
Operating Margin (5Y Avg)-81.44%
EPS Excl Extra (Annual)$-0.74
CapEx CAGR (5Y)-25.10%
26-Week Price Return27.81%
Quick Ratio (Annual)9.22x
13-Week Price Return-40.64%
Total Debt / Equity (Annual)0.63x
Current Ratio (Quarterly)10.22x
Enterprise Value$169.22
Revenue / Share Growth (5Y)19.32%
Asset Turnover (TTM)0.64x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.43x
Pretax Margin (Annual)-49.66%
Cash / Share (Annual)$1.72
3-Month Return Std Dev80.11%
Gross Margin (5Y Avg)84.57%
Net Income / Employee (TTM)$-0
ROE (Last FY)-60.10%
Net Interest Coverage (Annual)-31.86x
EPS Basic Excl Extra (Annual)$-0.74
Receivables Turnover (TTM)7.54x
Total Debt / Equity (Quarterly)0.63x
EPS Incl Extra (TTM)$-0.74
Receivables Turnover (Annual)7.54x
ROI (TTM)-35.28%
P/S Ratio (TTM)2.86x
Pretax Margin (5Y Avg)-86.26%
Revenue / Share (Annual)$1.48
Tangible BV / Share (Annual)$3.31
Price vs S&P 500 (52W)21.61%
Year-to-Date Return-48.42%
5-Day Price Return10.84%
EPS Normalized (Annual)$-0.74
ROA (5Y Avg)-33.13%
Net Profit Margin (Annual)-49.67%
Month-to-Date Return8.49%
Cash Flow / Share (TTM)$-1.26
EBITD / Share (Annual)$-0.70
Operating Margin (Annual)-47.95%
LT Debt / Equity (Annual)0.63x
ROI (5Y Avg)-36.37%
LT Debt / Equity (Quarterly)0.63x
EPS Basic Excl Extra (TTM)$-0.74
P/TBV (Quarterly)1.19x
P/B Ratio (Annual)6.56x
Inventory Turnover (TTM)1.43x
Pretax Margin (TTM)-49.66%
Book Value / Share (Annual)$1.20
Price vs S&P 500 (13W)-43.50%
Beta2.46x
Revenue / Share (TTM)$1.46
ROE (TTM)-55.72%
52-Week Low$2.40
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.85
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
SGHTSight Sciences, Inc. Common Stock | 2.86x | 22.86% | 86.95% | -47.96% | $4.36 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Sight Sciences develops surgical and nonsurgical medical devices for treating eye diseases. The company's lead product, the OMNI Surgical System, treats primary open-angle glaucoma through minimally invasive canaloplasty and trabeculotomy using a single corneal incision. The company also markets the TearCare System for dry eye treatment, with glaucoma products generating the majority of revenue.